Transcription of COSENTYX (secukinumab) injection, for subcutaneous use o ...
{{id}} {{{paragraph}}}
Example: bachelor of science
COSENTYX (secukinumab) injection, for subcutaneous use o ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COSENTYX safely and effectively. See full prescribing information for COSENTYX . COSENTYX (secukinumab) injection, for subcutaneous useCOSENTYX (secukinumab) for injection, for subcutaneous use Initial Approval: 2015 -----------------------------RECENT MAJOR CHANGES-------------------------Dosage and Administration ( , , , , )5/2023-----------------------------INDI CATIONS AND USAGE-------------------------- COSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy ( ) active psoriatic arthritis (PsA) in patients 2 years of age and older ( ) adults with active ankylosing spondylitis (AS) ( ) adults with active non- radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation ( ) active enthesitis-related arthritis (ERA) in patients 4 years of age and older ( ) -----------------------DOSAGE AND ADMINISTRATION----------------------- Prior to COSENTYX initiation, complete all age-appropriate vaccinati
COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. 1.5 Enthesitis-Related Arthritis COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: